Watanabe A, Yoriki R, Nakagawa M, Sado S, Yamada T, Kusumoto Y, Tamaki H, Hongo S
Dept. of Surgery, Nara Prefectural Nara Hospital.
Gan To Kagaku Ryoho. 2001 Nov;28(12):1913-6.
A 74-year-old female patient underwent total gastrectomy, splenectomy and D2 lymph node dissection for gastric cancer with non-dissectible paraaortic lymph node metastasis. Pathological examination revealed a high level of metastasis of dissected lymph nodes. The patient received daily oral administration of 100 mg TS-1, a novel oral anticancer agent. Each treatment course consisted of a four-week administration followed by two drug-free weeks. A partial response was obtained after the second course and a complete response was observed in the middle of the fourth and after the sixth course. The treatment was stopped because of grade 2 anemia in the middle of the seventh course, but no other adverse effect was observed. Complete response of the treatment persisted for twelve months and the patient has now been in good health without a recurrence for twenty months after surgery. Although the prognosis of gastric cancer with a high level of lymph node metastasis is poor, TS-1 therapy may have a potent efficacy in gastric cancer patients with a high level of lymph node metastasis such as the current case.
一名74岁女性患者因胃癌伴不可切除的主动脉旁淋巴结转移接受了全胃切除术、脾切除术及D2淋巴结清扫术。病理检查显示清扫淋巴结转移程度高。该患者每日口服100 mg新型口服抗癌药替吉奥（TS-1）。每个疗程包括四周给药，随后停药两周。第二个疗程后获得部分缓解，在第四个疗程中期和第六个疗程后观察到完全缓解。第七个疗程中期因2级贫血停止治疗，但未观察到其他不良反应。治疗的完全缓解持续了12个月，患者术后20个月一直健康，无复发。尽管淋巴结转移程度高的胃癌预后较差，但替吉奥治疗可能对如本例这种淋巴结转移程度高的胃癌患者有显著疗效。
